Company Profiles

driven by the PitchBook Platform

Tarsa Therapeutics

Description

Developer of therapies for the treatment and prevention of postmenopausal osteoporosis and related bone diseases. The company offers an oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable.

2009

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$3.25M

Latest Deal Amount

$87.8M

Total Amount Raised

Description

Developer of therapies for the treatment and prevention of postmenopausal osteoporosis and related bone diseases. The company offers an oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable.

Website:

www.tarsatherapeutics.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

8 Penn Center, 1628 John F. Kennedy Boulevard Suite 1400 Philadelphia, PA 19103United States +1 (267) 273-7940
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Tarsa Therapeutics's full profile, request a free trial.

    Tarsa Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Tarsa Therapeutics Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Tarsa Therapeutics Investors (5)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Foresite Capital ManagementVenture CapitalMinority000 0000000 0000
    MarkerVenture CapitalMinority000 0000000 0000
    MVM Life Science PartnersVenture CapitalMinority000 0000000 0000
    NovoCorporate Venture CapitalMinority000 0000000 0000
    Quaker PartnersVenture CapitalMinority000 0000000 0000
    Foresite Capital Management Venture Capital
    Marker Venture Capital
    MVM Life Science Partners Venture Capital
    Novo Corporate Venture Capital
    Quaker Partners Venture Capital

    Tarsa Therapeutics Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    David BrandChief Executive Officer, President, Board Member & Co-Founder
    James Gilligan Ph.DChief Scientific Officer & Co-Founder
    Ani RailkarDirector, CMC
    George MaurerVice President, CMC & Supply
    Nicholas LaBella Jr.Vice President, Global Regulatory Affairs
    David Brand Chief Executive Officer, President, Board Member & Co-Founder
    James Gilligan Ph.D Chief Scientific Officer & Co-Founder
    Ani Railkar Director, CMC
    George Maurer Vice President, CMC & Supply
    Nicholas LaBella Jr. Vice President, Global Regulatory Affairs

    Tarsa Therapeutics Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    Daniel SolandSelfBoard Member000 0000
    David BrandTarsa TherapeuticsChief Executive Officer, President, Board Member & Co-Founder000 0000
    Derek FergusonSelfDirector000 0000
    Eric Bednarski Ph.DMVM Life Science PartnersPartner000 0000
    James Tananbaum MDForesite Capital ManagementFounder, Managing Director & Chief Executive Officer000 0000
    Daniel Soland Board Member Self
    David Brand Chief Executive Officer, President, Board Member & Co-Founder Tarsa Therapeutics
    Derek Ferguson Director Self
    Eric Bednarski Ph.D Partner MVM Life Science Partners
    James Tananbaum MD Founder, Managing Director & Chief Executive Officer Foresite Capital Management
    Request full access to PitchBook